SAN DIEGO–(BUSINESS WIRE)–Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational benefits to patients with life-threatening diseases, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation for its investigational therapy, taladegib (ENV-101), for the treatment of idiopathic pulmonary fibrosis (IPF). IPF is a life-threatening lung disease characterized by
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
